Pfizer (PFE) Receives ‘Analyst’ Rating

Pfizer (PFE) : Zacks Investment Research ranks Pfizer (PFE) as 3, which is a Hold recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.92, which indicates as a Buy.

Pfizer (PFE) : The highest short term price target forecast on Pfizer (PFE) is $54 and the lowest target price is $33. A total of 12 equity analysts are currently covering the company. The average price of all the analysts is $39.5 with a standard deviation of $5.62.


Also, Major Brokerage house, Jefferies maintains its ratings on Pfizer (NYSE:PFE). In the latest research report, Jefferies lowers the target price from $41.5 per share to $40 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on August 4, 2016.

Pfizer (NYSE:PFE): After opening at $33.89, the stock dipped to an intraday low of $33.55 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $34.33 and the buying power remained strong till the end. The stock closed at $34.14 for the day, a gain of 0.59% for the day session. The total traded volume was 20,852,944. The stocks close on the previous trading day was $33.94.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.